Within the Iodine-124 market, application segmentation is the primary driver of revenue distribution. Diagnostic imaging, particularly positron emission tomography (PET), accounts for the largest share, estimated at 55 % of total sales. This dominance reflects the isotope’s 4.2‑day half‑life, which aligns with clinical workflow and enables high‑resolution tumor visualization, thereby sustaining demand from oncology centers and imaging networks. Therapeutic research represents roughly 20 %, encompassing early‑phase trials that explore I-124‑guided dose‑escalation and theranostic strategies; the high specific activity of the isotope supports precise dosimetry, attracting pharmaceutical developers. Radiopharmaceutical production contributes 15 %, driven by contract manufacturing facilities that supply I-124‑labeled compounds to both diagnostic and therapeutic pipelines. Finally, preclinical studies occupy 10 %, where academic and biotech laboratories employ I-124 for biodistribution and pharmacokinetic profiling. Collectively, these application categories constitute the core of the Iodine-124 segmentation, each influencing the market size through distinct cost structures, regulatory pathways, and adoption rates.
